IDEXX Laboratories stock holds after Stifel keeps Buy rating

Published on 09/19/2026 at 12:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Stifel kept a Buy rating and a USD 675 target on IDEXX Laboratories stock on September 18, 2026. Q2 2026 adjusted EPS reached USD 4.27 on USD 1.22 billion revenue.

Moderne Veterinärdiagnostik-Labor mit Analysegeräten, Blutproben und Technikerin — IDEXX Laboratories US45168D1046 zeigt ein modernes Veterinärdiagnostik Labor mit Analysegeräten und Technikerin, Illustration mit AI erstellt.

IDEXX Laboratories stock (US45168D1046) trades near USD 506.48 after Stifel kept a Buy rating and a USD 675.00 price target on September 18, 2026. The move leaves the shares about USD 168.52 below that target and close to the 52-week low of USD 500.61, according to Investing.com.

Q2 beat still matters

The same report says IDEXX posted adjusted earnings of USD 4.27 per share in Q2 2026 on revenue of USD 1.22 billion, above consensus of USD 3.96 per share and USD 1.20 billion. Gross margin reached 64 percent, while recurring diagnostics revenue posted 10.3 percent organic growth.

That is the core investor debate: the quarterly beat was real, but the stock still traded at USD 506.48 as of September 18, 2026, below Stifel's USD 675.00 target. The report also said total revenue rose 10 percent year over year and management lifted full-year guidance.

Range and momentum

For chart watchers, the stock sat near its one-year floor at USD 500.61 and well below the 52-week high of USD 770.00 on September 18, 2026. Yahoo Finance listed IDEXX with a market capitalization of USD 40.308 billion on September 19, 2026, while MSN noted a year-to-date decline of 24.08 percent.

Trading view

IDEXX Laboratories stock closed near USD 506.48 on Nasdaq on September 18, 2026, with the 52-week range stretching from USD 500.61 to USD 770.00. For investors, the gap to the target and the 64 percent gross margin now frame the next leg more than the quarterly beat alone.